Novo Nordisk files for oral weight loss pill approval in China
Novo Nordisk announced Thursday that Chinese regulators had greenlit a review of its bid to market an oral…
Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
Novo Nordisk A/S First GLP-1 pill approved in the European Union for the treatment of obesity and overweight…
Novo Nordisk’s Oral Wegovy Wins EU Approval, but a Strict Dosing Regimen and Mounting Rivalry Chec
The European Commission’s green light for Novo Nordisk’s oral Wegovy tablet on 15 July 2026 marks the first…
Novo Nordisk’s Oral Wegovy Wins EU Approval – So Why Isn’t the Market Celebrating?
Novo Nordisk finally has what it has been fighting for: European regulators have cleared the oral version of…
Wegovy Pill Wins EU Approval, Yet Novo Nordisk’s Rally Faces a Jittery Wait for FDA and Earnings
The European Commission has handed Novo Nordisk a clear edge in the race to dominate the oral weight?loss…
Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
Novo Nordisk A/S First GLP-1 pill approved in the European Union for the treatment of obesity and overweight…
Novo Nordisk Broadens Arsenal with Implant Deal and MASH Approval as Buyback Sustains Momentum
Novo Nordisk is fighting back against Eli Lilly’s encroachment on multiple fronts — through a novel long-acting implant…
Novo Nordisk Gains UK MASH Approval but Overbought Charts and Cyber Probe Temper Euphoria
Novo Nordisk picked up a new regulatory win in Britain on 3 July 2026, when the MHRA granted…
Novo Nordisk: Court Victory and Pill Approval Propel Recovery, Yet 2026 Revenue Slump Casts a Shadow
Novo Nordisk has been handed a series of catalysts in quick succession — a landmark patent ruling in…
Novo Nordisk Clinches UK Pill Approval and US Medicare Win, but Competition Narrows the Path
Novo Nordisk has pulled off a rare double-catalyst week, securing both a European approval for its oral Wegovy…
Novo Nordisk Shares Jump 9% in a Week as Buyback, Pill Approval, and Court Win Converge
The Danish pharmaceutical giant has engineered a broad-based recovery, with multiple catalysts aligning to lift its stock. Novo…
Novo Nordisk Faces a High-Stakes Balancing Act: Wegovy Pill Approval vs. Escalating Cyber Threats
Novo Nordisk ended a week of stark contrasts with its shares stuck near EUR 38.90 — a modest…